



PRESS RELEASE, 7 August 2002

Perbio Science AB
Interim report January-June 2002
Continued strong growth

- Net sales up 24% to SEK 1,108 (896) million
- Operating profit before amortisation of goodwill up 28% to SEK 210 (164) million
- Profit after financial items up 25% to SEK 190 (152) million after exchange losses of SEK 2 million (gains of SEK 15 million) and up 40% excluding exchange rate effects
- Net profit up 26% to SEK 116 (92) million
- Strong interest in the innovative production technology at the new media factory in Logan, USA
- New raw materials base for serum production established in Canada

"Our operating margin increased to 18.0% from 17.2% for 2001 as a whole," says **CEO Mats Fischier**.

"Besides strong earnings growth, sales increased by 24% overall and by 23% excluding exchange rate effects.

"Perbio Science has continued to cement its position in the market. There was strong growth at the Cell Culture and Medical Device divisions and the Bioresearch division's protein business."

FURTHER INFORMATION

CEO Mats Fischier

tel +46 42 26 90 91 or +46 70 595 18 21

CFO Claes Wentzel

tel +46 42 26 90 92 or +46 70 862 01 22

More information on Perbio Science can also be found on our website at www.perbio.com.